We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants

By LabMedica International staff writers
Posted on 14 Oct 2021
Print article
Image: New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants (Photo courtesy of Trinity College Dublin)
Image: New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants (Photo courtesy of Trinity College Dublin)

A team of researchers has developed a new nanomechanical technique for fast, one-step, immune-affinity tests, which can quantify the immune response induced by different COVID-19 variants in serum.

The technique developed by researchers at Trinity College Dublin (Dublin, Ireland) provides a new tool for tracking infection immunity over time and for analysing new vaccine candidates. The team’s specific quantitative assay enables direct classification of variant-binding properties for screening emerging variants. The major advantage of the newly developed technique with respect to (existing, commonly used) ELISA tests is that while it is equally sensitive – with added single amino-acid resolution – and able to directly detect multiple variants by in situ differential analysis, it can also do so in a mere fraction of the time.

The researchers focused on COVID-19 variants of concern and their generated humoral immune response. Humoral immunity is an antibody-mediated response that occurs when foreign material is detected in the body. Given that the COVID-19 virus has developed substantial mutations in the spike protein, this can undermine the efficacy of current vaccines and monoclonal antibody therapies. The new technology developed by team of researchers can assist vaccine development studies in phase 1-3, with focus on comparing protection patterns and analyzing novel vaccine candidates.

“Our measurements match the statistical analysis of, for example, the transmissibility of the alpha-variant that can otherwise only be gained by analyzing the development of the disease proliferation within a population over weeks. We believe that this new technology can improve and speed up the public health guidance process,” said Professor Martin Hegner, Principal Investigator in the Trinity Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) and Trinity’s School of Physics. “The direct technique greatly simplifies the preparation protocol that in ELISA includes many washings and waiting steps, hence reducing the amount of consumables needed and thus the relative cost. It will therefore be well suited to use in emergency situations.”

Related Links:
Trinity College Dublin 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.